Rentschler Biopharma and Leukocare have reported the success of the first year of their strategic alliance, incorporating formulation development in each step of the biopharmaceutical development and manufacturing process.
Success
“The first year of this strategic alliance between Rentschler Biopharma and Leukocare was a great success and has proven our rationale to deliver best-in-class formulation throughout the biopharmaceutical value chain,” commented Dr Frank Mathias, CEO of Rentschler Biopharma. “By repositioning formulation as a key success factor in biopharmaceutical development, we have initiated vital discussions throughout the industry. Both existing and new clients have responded very positively to this new strategy.”
“Over the past year, our alliance has received a great deal of interest and recognition for this striking approach,” stated Michael Scholl, CEO of Leukocare. “We have been able to expand our client base, particularly in the US, and look forward to acquiring further clients and development projects in the near term. This innovative approach provides our current and future clients significant competitive advantages, enabling them to exploit the full potential of their products and markets.”
Leukocare is the specialised technology partner and the exclusive formulation developer for Rentschler Biopharma's biopharmaceutical development business. Rentschler Biopharma is the first and only contract development and manufacturing organisation (CDMO) to have access to Leukocare's patented SPS formulation technologies. As part of the original agreement, Rentschler Biopharma holds a 10% stake in Leukocare and Dr Frank Mathias is a member of Leukocare's board of directors.